Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 9 Issue 3, March 2010

In This Issue

Top of page ⤴

Comment

Top of page ⤴

News and Analysis

  • Recent deal-making and promising clinical trial results for antibody-based antibacterial agents highlight the potential of such therapeutics to tackle multidrug resistant bacteria.

    • Andy Extance
    News and Analysis
Top of page ⤴

News Feature

Top of page ⤴

News in Brief

Top of page ⤴

Biobusiness Briefs

Top of page ⤴

News and Analysis

Top of page ⤴

Patent Watch

Top of page ⤴

An Audience With

  • A pioneer of evidence-based medicine discusses how mathematical models can be used to understand the likely cost and health-care outcomes of therapies.

    • Bethan Hughes
    An Audience With
Top of page ⤴

From the Analyst's Couch

Top of page ⤴

Fresh from the Pipeline

    • Bruce Zuraw
    • Uma Yasothan
    • Peter Kirkpatrick
    Fresh from the Pipeline
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Opinion

  • Advanced therapy medicinal products (ATMPs) offer hope for the treatment of diseases for which therapeutic options are currently lacking. This article discusses the regulatory role of the Committee for Advanced Therapies at the European Medicines Agency, highlighting issues and challenges observed in ATMP development.

    • Christian K. Schneider
    • Paula Salmikangas
    • Patrick Celis
    Opinion
Top of page ⤴

Analysis

  • Improving R&D productivity is crucial to ensuring the future viability of the pharmaceutical industry and advances in health care. This article presents a detailed analysis, based on comprehensive, recent, industry-wide data, to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity, and proposes strategies that could have the most substantial impact in enhancing R&D productivity.

    • Steven M. Paul
    • Daniel S. Mytelka
    • Aaron L. Schacht
    Analysis
Top of page ⤴

Review Article

  • Membrane transporters play an important part in determining the pharmacokinetics of many drugs. Here, the International Transporter Consortium discusses key transporters with a role in drug absorption and disposition, and provides guidance for clinical drug interaction studies.

    • Kathleen M. Giacomini
    • Shiew-Mei Huang
    • Lei Zhang
    Review Article
  • Diseases such as Alzheimer's disease and systemic amyloidoses are associated with inappropriate deposition of proteins containing a characteristic highly ordered, β-sheet-rich structural motif. The common structural and pathogenic features of these diverse protein aggregation diseases may offer opportunities to develop overarching therapeutic strategies.

    • Adriano Aguzzi
    • Tracy O'Connor
    Review Article
Top of page ⤴

Careers and Recruitment

Top of page ⤴

Search

Quick links